BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

623 related articles for article (PubMed ID: 32971232)

  • 1. How specific are the conformation-specific α-synuclein antibodies? Characterization and validation of 16 α-synuclein conformation-specific antibodies using well-characterized preparations of α-synuclein monomers, fibrils and oligomers with distinct structures and morphology.
    Kumar ST; Jagannath S; Francois C; Vanderstichele H; Stoops E; Lashuel HA
    Neurobiol Dis; 2020 Dec; 146():105086. PubMed ID: 32971232
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Generation and characterization of novel conformation-specific monoclonal antibodies for α-synuclein pathology.
    Vaikath NN; Majbour NK; Paleologou KE; Ardah MT; van Dam E; van de Berg WD; Forrest SL; Parkkinen L; Gai WP; Hattori N; Takanashi M; Lee SJ; Mann DM; Imai Y; Halliday GM; Li JY; El-Agnaf OM
    Neurobiol Dis; 2015 Jul; 79():81-99. PubMed ID: 25937088
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A simple, versatile and robust centrifugation-based filtration protocol for the isolation and quantification of α-synuclein monomers, oligomers and fibrils: Towards improving experimental reproducibility in α-synuclein research.
    Kumar ST; Donzelli S; Chiki A; Syed MMK; Lashuel HA
    J Neurochem; 2020 Apr; 153(1):103-119. PubMed ID: 31925956
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fibrillar form of α-synuclein-specific scFv antibody inhibits α-synuclein seeds induced aggregation and toxicity.
    Gupta V; Salim S; Hmila I; Vaikath NN; Sudhakaran IP; Ghanem SS; Majbour NK; Abdulla SA; Emara MM; Abdesselem HB; Lukacsovich T; Erskine D; El-Agnaf OMA
    Sci Rep; 2020 May; 10(1):8137. PubMed ID: 32424162
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Distinct region-specific alpha-synuclein oligomers in A53T transgenic mice: implications for neurodegeneration.
    Tsika E; Moysidou M; Guo J; Cushman M; Gannon P; Sandaltzopoulos R; Giasson BI; Krainc D; Ischiropoulos H; Mazzulli JR
    J Neurosci; 2010 Mar; 30(9):3409-18. PubMed ID: 20203200
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Stabilization of α-synuclein oligomers using formaldehyde.
    Ruesink H; Reimer L; Gregersen E; Moeller A; Betzer C; Jensen PH
    PLoS One; 2019; 14(10):e0216764. PubMed ID: 31603909
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structural and Biophysical Characterization of Stable Alpha-Synuclein Oligomers.
    Vaikath N; Sudhakaran I; Abdi I; Gupta V; Majbour N; Ghanem S; Abdesselem H; Vekrellis K; El-Agnaf O
    Int J Mol Sci; 2022 Nov; 23(23):. PubMed ID: 36498957
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel antibodies detect additional α-synuclein pathology in synucleinopathies: potential development for immunotherapy.
    Nimmo JT; Verma A; Dodart JC; Wang CY; Savistchenko J; Melki R; Carare RO; Nicoll JAR
    Alzheimers Res Ther; 2020 Nov; 12(1):159. PubMed ID: 33256825
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Detection of elevated levels of soluble alpha-synuclein oligomers in post-mortem brain extracts from patients with dementia with Lewy bodies.
    Paleologou KE; Kragh CL; Mann DM; Salem SA; Al-Shami R; Allsop D; Hassan AH; Jensen PH; El-Agnaf OM
    Brain; 2009 Apr; 132(Pt 4):1093-101. PubMed ID: 19155272
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel conformation-selective alpha-synuclein antibodies raised against different in vitro fibril forms show distinct patterns of Lewy pathology in Parkinson's disease.
    Covell DJ; Robinson JL; Akhtar RS; Grossman M; Weintraub D; Bucklin HM; Pitkin RM; Riddle D; Yousef A; Trojanowski JQ; Lee VM
    Neuropathol Appl Neurobiol; 2017 Dec; 43(7):604-620. PubMed ID: 28386933
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Defining α-synuclein species responsible for Parkinson's disease phenotypes in mice.
    Froula JM; Castellana-Cruz M; Anabtawi NM; Camino JD; Chen SW; Thrasher DR; Freire J; Yazdi AA; Fleming S; Dobson CM; Kumita JR; Cremades N; Volpicelli-Daley LA
    J Biol Chem; 2019 Jul; 294(27):10392-10406. PubMed ID: 31142553
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pathological interface between oligomeric alpha-synuclein and tau in synucleinopathies.
    Sengupta U; Guerrero-Muñoz MJ; Castillo-Carranza DL; Lasagna-Reeves CA; Gerson JE; Paulucci-Holthauzen AA; Krishnamurthy S; Farhed M; Jackson GR; Kayed R
    Biol Psychiatry; 2015 Nov; 78(10):672-83. PubMed ID: 25676491
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Selectivity of Lewy body protein interactions along the aggregation pathway of α-synuclein.
    Leitão ADG; Rudolffi-Soto P; Chappard A; Bhumkar A; Lau D; Hunter DJB; Gambin Y; Sierecki E
    Commun Biol; 2021 Sep; 4(1):1124. PubMed ID: 34556785
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Revisiting the role of 3-nitrotyrosine residues in the formation of alpha-synuclein oligomers and fibrils.
    Chavarría C; Ivagnes R; Zeida A; Piñeyro MD; Souza JM
    Arch Biochem Biophys; 2024 Feb; 752():109858. PubMed ID: 38104957
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Scutellarin inhibits the uninduced and metal-induced aggregation of α-Synuclein and disaggregates preformed fibrils: implications for Parkinson's disease.
    Zaidi FK; Deep S
    Biochem J; 2020 Feb; 477(3):645-670. PubMed ID: 31939603
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Polymorphic Alpha-Synuclein Oligomers: Characterization and Differential Detection with Novel Corresponding Antibodies.
    Moore K; Sengupta U; Puangmalai N; Bhatt N; Kayed R
    Mol Neurobiol; 2023 May; 60(5):2691-2705. PubMed ID: 36707462
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neurotoxic conversion of beta-synuclein: a novel approach to generate a transgenic mouse model of synucleinopathies?
    Fujita M; Sekigawa A; Sekiyama K; Sugama S; Hashimoto M
    J Neurol; 2009 Aug; 256 Suppl 3():286-92. PubMed ID: 19711118
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sensitive fluorescence polarization technique for rapid screening of alpha-synuclein oligomerization/fibrillization inhibitors.
    Luk KC; Hyde EG; Trojanowski JQ; Lee VM
    Biochemistry; 2007 Nov; 46(44):12522-9. PubMed ID: 17927212
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Calpain-cleavage of alpha-synuclein: connecting proteolytic processing to disease-linked aggregation.
    Dufty BM; Warner LR; Hou ST; Jiang SX; Gomez-Isla T; Leenhouts KM; Oxford JT; Feany MB; Masliah E; Rohn TT
    Am J Pathol; 2007 May; 170(5):1725-38. PubMed ID: 17456777
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Selection of DNA aptamers that recognize α-synuclein oligomers using a competitive screening method.
    Tsukakoshi K; Abe K; Sode K; Ikebukuro K
    Anal Chem; 2012 Jul; 84(13):5542-7. PubMed ID: 22697251
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.